AMP is WAC.
AMP is WAC is Apteka’s weekly newsletter breaking down what’s happening in health policy, what it means, and what to do about it. No jargon. No fluff. Just policy, to the point.
Get weekly policy updates.
No spam. Unsubscribe anytime. We respect your inbox.
"It becomes part of my thinking and influences how I approach my business."
— Senior Director of Product Strategy, PBM
- Issue briefs & white papers
Examples of Our Work.
A lot of what we do is behind-the-scenes, but here is what we can share.
- Medicare & Part D
Hope for the Best, Prepare for the Worst: IRA's Unintended Consequences for Part D
The most significant changes to Part D since its inception, and what three major provisions actually mean for Medicare beneficiaries.
Commissioned by MAPRx Coalition
- Medicare & Part D
Focus on Access: Medicare Part B Negotiations
Unanswered questions and unintended consequences as CMS moves into Part B negotiations, including impacts on Average Sales Price and provider viability.
Commissioned by Alliance for Patient Access (AfPA)
- Drug Pricing & Access
Why Maximum Fair Price is Not a Model for State Drug Pricing.
Medicare’s MFP looks like a ready-made benchmark for state drug affordability efforts. It’s not. This brief explains why it recreates the same access problems as any upper payment limit.
Commissioned by Rare Access Action Project (RAAP)
- Drug Pricing & Access
Focus on Access: How Most Favored Nation Could Fail Patients
MFN sounds straightforward but does little for patient affordability, and carries real risks for pharmaceutical innovation and U.S.-based R&D.
Commissioned by Alliance for Patient Access (AfPA)
- Drug Pricing & Access
Solving for Access and Affordability: PDABs Are Not the Answer
Prescription Drug Affordability Boards haven’t delivered on their promise, and the unintended consequences hit patients with rare diseases hardest.
Commissioned by Rare Access Action Project (RAAP)
- Drug Pricing & Access
Focus on Access: Value of Treatment
Only 13% of health spending goes to prescription drugs, and the value they provide extends far beyond direct cost.
Commissioned by Alliance for Patient Access (AfPA)
- Biosimilars
Nurturing the Potential of the Biosimilar Market
Almost a decade in, are U.S. biosimilars delivering on cost, access, and patient choice? What’s working, what’s not, and what needs to change.
Commissioned by Alliance for Patient Access and the Biologics Prescribers Collaborative
"Often exploring the impact of policymaking on rare patients is the very last thing that crosses policymakers' minds. Apteka has provided substantive and credible examinations of specific policies and their impact on patient access. Jennifer goes the extra mile to provide understanding and insights to our patient audiences through workshops and webinars. Apteka is part of our team."
— Executive Director, Patient Advocacy group
Policy,
to the point.
Actions
Socials
© 2026 Apteka. All rights reserved.
